Related Experiment Videos
[Upper urinary tract tumors following bladder cancer]
K Yoshimura1, Y Tomooka, O Maeda
1Department of Urology, Center for Adult Diseases, Osaka.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology
|September 1, 1990
Summary
Patients with transitional cell carcinoma of the urinary bladder face a 2.3% risk of developing upper urothelial cancer. High-risk groups include those with tumors near orifices or multifocal G2 bladder cancer.
Area of Science:
- Urology
- Oncology
- Cancer Research
Context:
- Transitional cell carcinoma (TCC) of the urinary bladder is a significant health concern.
- Long-term follow-up is crucial for identifying secondary malignancies.
- Understanding recurrence patterns aids in risk stratification and management.
Purpose:
- To determine the incidence and risk factors for upper urinary tract tumors in patients initially treated for bladder cancer.
- To analyze the time interval between treatments and survival rates for upper tract tumors.
Summary:
- A study of 795 patients with primary bladder TCC revealed an overall incidence of 2.3% for subsequent upper urothelial cancer.
- High-risk patient groups identified include those with tumors near orifices, recurrent cancer under long-term bladder-preserving treatment, and multifocal G2 tumors.
- The median interval to upper tract tumor diagnosis was 20 months, with a 5-year survival rate of 31.7% post-treatment.
Impact:
- Identifies specific patient subgroups at higher risk for upper urinary tract recurrences.
- Informs clinical surveillance strategies and personalized treatment approaches for bladder cancer survivors.
- Contributes to improved outcomes for patients diagnosed with secondary upper urothelial malignancies.